Share this

Mark commented, “It’s a privilege and an honour to be invited to lead the next phase in Charnwood’s commercial development. I’m very much looking forward to engaging with the team and particularly our customers, to help deliver the first step towards life changing medicines for patients.”

Steve Allin, CEO of Charnwood Molecular added: “Mark joins us at an exciting time, as we begin to deliver our vision of becoming the provider of choice for drug discovery and development projects. Marks commercial acumen, experience and leadership as we begin to add new service lines, and undertake more complex integrated projects whilst operating from a new, world-class facility in 2021, will be invaluable in realising our strategic plan and in developing deep and meaningful collaborative partnerships with our global client base.”